2082:TADAWULACWA Power Company Analysis
Data as of 2026-07-03 - not real-time
SAR 194.30
Latest Price
6/10Risk
Risk Level: Medium
Executive Summary
ACWA Power is trading just below its 20‑day simple moving average, with a neutral RSI around 50 and a bearish MACD histogram, suggesting short‑term momentum weakness. Volume is on a decreasing trend and 30‑day volatility is high at roughly 35%, while beta is near zero, indicating the stock moves independently of the broader market. The market price of SAR 194 is far above the DCF‑derived fair value of SAR 25 and the trailing P/E of 83 versus an industry average of 21, placing the stock in an extreme‑greed sentiment environment. Fundamentally, revenue growth is modest at 2.8% and operating margins are respectable, yet the company carries a very high debt‑to‑equity ratio (~98) and negative free cash flow, with no dividend paid.
The recent announcement of a 5,000 MW clean‑energy platform partnership in the Philippines adds a growth catalyst, but the benefits will likely materialize over several years and must be weighed against the current valuation gap and balance‑sheet strain.
The recent announcement of a 5,000 MW clean‑energy platform partnership in the Philippines adds a growth catalyst, but the benefits will likely materialize over several years and must be weighed against the current valuation gap and balance‑sheet strain.
Market Outlook
Short Term
< 1 yearCautious
Model confidence: 7/10
Key Factors
- Bearish MACD signal and price below short‑term SMA
- Extreme overvaluation relative to DCF and peers
- Decreasing volume and high short‑term volatility
Medium Term
1–3 yearsNeutral
Model confidence: 6/10
Key Factors
- Strategic clean‑energy partnership in the Philippines
- Modest revenue growth and solid operating margins
- Continued valuation premium and high debt load
Long Term
> 3 yearsNeutral
Model confidence: 5/10
Key Factors
- Long‑term power purchase agreements and green hydrogen pipeline
- Persistent balance‑sheet leverage and negative free cash flow
- Potential valuation correction as market expectations normalize
Key Metrics & Analysis
Financial Health
Revenue Growth2.80%
Profit Margin23.70%
P/E Ratio83.4
ROE7.05%
ROA2.30%
Debt/Equity97.72
P/B Ratio5.1
Op. Cash FlowSAR4.1B
Free Cash FlowSAR-3375674112
Industry P/E21.1
Technical Analysis
TrendNeutral
RSI51.4
SupportSAR 182.30
ResistanceSAR 206.90
MA 20SAR 196.84
MA 50SAR 186.41
MA 200SAR 190.85
MACDBearish
VolumeDecreasing
Fear & Greed Index93.04
Valuation
Fair ValueSAR 25.09
Target PriceSAR 145.00
Upside/Downside-25.37%
GradeOvervalued
TypeValue
Risk Assessment
Beta0.08
Volatility34.69%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskLow
Liquidity RiskHigh
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.